Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01271790 · ClinicalTrials.gov registry record · Phase 2
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
NCT01271790: Completed Phase 2 study, sponsored by Gilead Sciences.
NCT01271790 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 245 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01271790, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
Study Summary
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
Primary Outcome
Sustained virologic response (SVR) defined as undetectable hepatitis C virus (HCV) RNA 24 weeks after treatment cessation
Interventions
- DRUG GS-9451
- DRUG Tegobuvir (GS-9190)
- BIOLOGICAL Pegasys®
- DRUG Copegus®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01271790 record still lists
NCT01271790 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% higher).
The record links to 0 conditions, and to 4 interventions - of which GS-9451 is the first listed.
NCT01271790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01271790 about?
NCT01271790 is a clinical study titled "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C". This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
What is the current status of trial NCT01271790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2010-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01271790?
The interventions under investigation include: GS-9451 (DRUG), Tegobuvir (GS-9190) (DRUG), Pegasys® (BIOLOGICAL), Copegus® (DRUG).
Who is sponsoring clinical trial NCT01271790?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01271790's enrollment target sits among peer trials
245 234th of 2000 higher than 1,766 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia